mFLUSIVA Has MORE Side Effects Than Standard-Dose Flu Vaccines, But Is Approved for Ages 50 and Older
mFLUSIVA actually causes MORE side effects than standard-dose influenza vaccines, not fewer—however, it is FDA-approved for adults aged 50 years and older. 1
Age Indication
mFLUSIVA is indicated for adults ≥50 years of age, not just 65 and older. The FDA label explicitly states approval for persons 50 years and older, with accelerated approval for those ≥65 years based on immune responses 1.
Side Effect Profile: Higher Reactogenicity
Key Finding from Clinical Trials
In the pivotal Phase 3 trial (NCT06602024) involving over 40,000 participants, solicited adverse reactions were reported MORE frequently with mFLUSIVA compared to standard-dose vaccines 1.
Specific Side Effect Rates
For adults 50-64 years:
- Injection site pain: 68.7%
- Fatigue: 48.1%
- Headache: 41.9%
- Myalgia: 40.6%
- Arthralgia: 31.5%
- Chills: 27.5%
- Axillary swelling/tenderness: 20.3% 1
For adults ≥65 years:
- Injection site pain: 62.9%
- Fatigue: 42.1%
- Headache: 33.7%
- Myalgia: 30.2%
- Arthralgia: 24.1%
- Chills: 18.1%
- Axillary swelling/tenderness: 14.2% 1
Important Context
The increased side effects are expected and acceptable because:
- Most reactions were Grade 1 or 2 (mild to moderate)
- Median duration was only 2 days
- Median onset was 2 days post-vaccination 1
The Trade-Off: Better Protection Despite More Side Effects
This pattern mirrors what we see with other enhanced influenza vaccines. High-dose vaccines consistently show:
- Superior immunogenicity (higher antibody responses) 2, 3
- Better clinical protection against laboratory-confirmed influenza 4, 5
- Reduced hospitalizations for influenza and cardiovascular complications 6
- Increased local and systemic reactions compared to standard-dose 4, 7
Clinical Recommendation Algorithm
For patients aged 50-64 years:
- Use mFLUSIVA if patient can tolerate 1-2 days of increased injection site pain and systemic symptoms
- Consider standard-dose if patient has concerns about reactogenicity or prior severe reactions to vaccines
For patients aged ≥65 years:
- Preferentially recommend mFLUSIVA or other enhanced vaccines (high-dose, adjuvanted, or recombinant) per ACIP guidelines 8
- The increased side effects are outweighed by superior protection in this high-risk population
- Note that side effect rates are actually slightly lower in the ≥65 age group compared to 50-64 year-olds 1
Important Safety Considerations
Contraindications
- History of severe allergic reaction (anaphylaxis) to mFLUSIVA or its components 1
- If Guillain-Barré syndrome occurred within 6 weeks of prior influenza vaccination, carefully weigh risks/benefits 9, 1
Common Pitfall to Avoid
Do not confuse "more side effects" with "unsafe." The increased reactogenicity reflects enhanced immune stimulation, which translates to better protection. The safety profile remains acceptable with no new safety concerns identified 1.
Serious Adverse Events
Importantly, high-dose vaccines like mFLUSIVA probably cause FEWER serious adverse events compared to standard-dose vaccines, despite the increased minor reactions 4.